Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Factors Associated With Otolaryngologists Performing Tracheotomy
Soliman, Shady , Panuganti, Bharat , Francis, David O. , Klebaner, Dasha, Asturias, Alicia , Alattar, Ali , Wood, Samuel , Terry, M. C. , Bryson, Paul C. , Tipton, Courtney B. , Zhao, Elise E. , Maria, Chloe Santa , Sung, C. Kwang , Lao, Wilson P. , Thompson, Jordan M. , Crawley, Brianna K. , Rosen, Sarah P. , Berezovsky, Anna , Hennesy, Theresa B. , Joseph, Ian T. , Sarhadi, Kamron, Kuhn, Maggie A. , Abdel‐Aty, Yassmeen , Kennedy, Maeve M. , Weissbrod, Philip A. , Abdel-Aty, Yassmeen, Soliman, Shady I , Sung, C K , Weissbrod, Philip A , Pang, John , Terry, Morgan, O'Rourke, Ashli , Grimm, David R. , Kupfer, Robbi A. , Clary, Matthew S. , Lott, David G.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | October 5, 2023 | Volume: 149 | Issue: 12 | Pages: 1066

10.1001/jamaoto.2023.2698 | PMID 37796485 Get It

ImportanceTracheotomies are frequently performed by nonotolaryngology services. The factors that determine which specialty performs the procedure are not defined in the literature but may be influenced by tracheotomy approach (open vs percutaneous) and other clinicodemographic factors.ObjectiveTo evaluate demographic and clinical characteristics associated with tracheotomies performed by otolaryngologists compared with other specialists and to differentiate those factors from factors associated with use of open vs percutaneous tracheotomy.Design, Setting, and ParticipantsThis multicenter, retrospective cohort study included patients aged 18 years or older who underwent a tracheotomy for cardiopulmonary failure at 1 of 8 US academic institutions between January 1, 2013, and December 31, 2016. Data were analyzed from September 2022 to July 2023.ExposureTracheotomy.Main Outcomes and MeasuresThe primary outcome was factors associated with an otolaryngologist performing tracheotomy. The secondary outcome was factors associated with use of the open tracheotomy technique.ResultsA total of 2929 patients (mean [SD] age, 57.2 [17.2] years; 1751 [59.8%] male) who received a tracheotomy for cardiopulmonary failure (652 [22.3%] performed by otolaryngologists and 2277 [77.7%] by another service) were analyzed. Although 1664 of all tracheotomies (56.8%) were performed by an open approach, only 602 open tracheotomies (36.2%) were performed by otolaryngologists. Most tracheotomies performed by otolaryngologists (602 of 652 [92.3%]) used the open technique. Multivariable regression analysis revealed that self-reported Black race (odds ratio [OR], 1.89; 95% CI, 1.52-2.35), history of neck surgery (OR, 2.71; 95% CI, 2.06-3.57), antiplatelet and/or anticoagulation therapy (OR, 1.74; 95% CI, 1.29-2.36), and morbid obesity (OR, 1.54; 95% CI, 1.24-1.92) were associated with greater odds of an otolaryngologist performing tracheotomy. In contrast, history of neck surgery (OR, 1.36; 95% CI, 0.96-1.92), antiplatelet and/or anticoagulation therapy (OR, 0.80; 95% CI, 0.56-1.14), and morbid obesity (OR, 0.94; 95% CI, 0.74-1.19) were not associated with undergoing open tracheotomy when performed by any service, and Black race (OR, 0.56; 95% CI, 0.44-0.71) was associated with lesser odds of an open approach being used. Age-adjusted Charlson Comorbidity Index score greater than 4 was associated with greater odds of both an otolaryngologist performing tracheotomy (OR, 1.26; 95% CI, 1.03-1.53) and use of the open tracheotomy technique (OR, 1.48, 95% CI, 1.21-1.82).Conclusions and RelevanceIn this study, otolaryngologists were significantly more likely than other specialists to perform a tracheotomy for patients with history of neck surgery, morbid obesity, and ongoing anticoagulation therapy. These findings suggest that patients undergoing tracheotomy performed by an otolaryngologist are more likely to present with complex and challenging clinical characteristics.
Initial interactions with the FDA on developing a validation dataset as a medical device development tool
Hart, Steven N. , García, Víctor , Dudgeon, Sarah , Hanna, Matthew G. , Li, Xiaoxian , Blenman, Kim , Elfer, Katherine , Salgado, Roberto , Saltz, Joel , Gupta, Rajarsi , Hytopoulos, Evangelos, Larsimont, Denis , Lennerz, Jochen K. , Hart, Steven N , Blenman, Kim Rm , Saltz, Joel H , Gupta, Rajarsi R , Gallas, Brandon D , Lennerz, Jochen , Ly, Amy

Mayo Clinic

The Journal of Pathology | October 5, 2023 | Volume: 261 | Issue: 4 | Pages: 378-384

10.1002/path.6208 | PMID 37794720 Get It

AbstractQuantifying tumor‐infiltrating lymphocytes (TILs) in breast cancer tumors is a challenging task for pathologists. With the advent of whole slide imaging that digitizes glass slides, it is possible to apply computational models to quantify TILs for pathologists. Development of computational models requires significant time, expertise, consensus, and investment. To reduce this burden, we are preparing a dataset for developers to validate their models and a proposal to the Medical Device Development Tool (MDDT) program in the Center for Devices and Radiological Health of the U.S. Food and Drug Administration (FDA). If the FDA qualifies the dataset for its submitted context of use, model developers can use it in a regulatory submission within the qualified context of use without additional documentation. Our dataset aims at reducing the regulatory burden placed on developers of models that estimate the density of TILs and will allow head‐to‐head comparison of multiple computational models on the same data. In this paper, we discuss the MDDT preparation and submission process, including the feedback we received from our initial interactions with the FDA and propose how a qualified MDDT validation dataset could be a mechanism for open, fair, and consistent measures of computational model performance. Our experiences will help the community understand what the FDA considers relevant and appropriate (from the perspective of the submitter), at the early stages of the MDDT submission process, for validating stromal TIL density estimation models and other potential computational models. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Lithium Response in Bipolar Disorder is Associated with Focal Adhesion and PI3K-Akt Networks: A Multi-omics Replication Study
Ou, Anna , Adli, Mazda , Akiyama, Kazufumi , Akula, Nirmala , Amare, Azmeraw T. , Ardau, Raffaella , Arias, Bárbara , Aubry, Jean‐Michel , Bauer, Michael , Benabarre, Antonio , Bengesser, Susanne , Abesh, Bhattacharjee, Bui, Elise T. , Cervantes, Pablo , Chillotti, Caterina , Cichon, Sven , Clark, Scott R. , Cousins, David A. , Cruceanu, Cristiana , Degenhardt, Franziska , Ferensztajn‐Rochowiak, Ewa , Forstner, Andreas J. , Frisén, Louise , Frye, Mark A. , Gard, Sébastien, Grof, Paul , Gruber, Oliver , Kahn, Jean‐Pierre, Kassem, Layla, Kittel‐Schneider, Sarah , Dalkner, Nina , Laje, Gonzalo, Landén, Mikael , Lavebratt, Catharina , Leckband, Susan G. , López‐Jaramillo, Carlos , Maj, Mario , Mattheisen, Manuel , McCarthy, Michael J. , Mitjans, Marina , Mondimore, Francis M. , Nöthen, Markus M. , Ösby, Urban, Perlis, Roy H. , Pfennig, Andrea , Potash, James B. , Schalling, Martin , Schubert, Klaus Oliver , Schweizer, Barbara , Severino, Giovanni , Shekhtman, Tatyana , Shilling, Paul D. , Shimoda, Kazutaka , Simhandl, Christian , Slaney, Claire , Stamm, Thomas , Tighe, Sarah K., Volkert, Julia, Witt, Stephanie H. , Zandi, Peter P. , Zompo, Maria Del , Ou, Anna , Alda, Martin , Amare, Azmeraw , Arias, Bárbara , Bauer, M , Baune, Bernhard , Biernacka, Joanna , Chen, Hsi-Chung , Clark, Scott , Cruceanu, Cristiana , Czerski, Piotr , DePaulo, J Raymond , Etain, B , Forstner, Andreas J , Frye, Mark , Fullerton, Janice M , Garnham, Julie , Grigoroiu-Serbanescu, Maria , Hashimoto, Ryota , Hauser, Joanna , Heilbronner, Urs , Hou, Liping , Jamain, Stéphane , Kato, Tadafumi , Kuo, Po-Hsiu , Kusumi, Ichiro , Landén, Mikael , Lavebratt, Catharina , Leboyer, Marion , Marie-Claire, Cynthia , McMahon, Francis , Mitchell, Philip B , Mitjans, Marina , Nievergelt, Caroline M , Nöthen, Markus M , Novak, Tomas , Ozaki, Norio , Papiol, Sergi , Reif, Andreas , Reininghaus, Eva , Rietschel, Marcella , Rouleau, Guy Armand , Rybakowski, Janusz K , Schalling, Martin , Schofield, Peter R , Schubert, Klaus Oliver , Schulze, Thomas , Severino, Giovanni , Shilling, Paul , Shimoda, Kazutaka , Squassina, Alessio , Turecki, Gustavo , Vieta, E , Witt, Stephanie H , Wray, Naomi , Del Zompo, Maria , Cichon, Sven , López-Jaramillo, Carlos , Kittel-Schneider, Sarah , McCarthy, Michael , Perlis, Roy H , Kelsoe, John R , Jiang, Qingfei , Alda, Martin , Backlund, Lena , Banzato, Cláudio E. M. , Bellivier, Frank , Biernacka, Joanna M. , Chen, Guo‐Bo , Chen, Hsi‐Chung , Colom, Francesc , Czerski, Piotr M. , Dantas, Clarissa de Rosalmeida , Dayer, Alexandre G. , Étain, Bruno , Falkai, Peter , Fellendorf, Frederike T. , Fullerton, Janice M. , Goes, Fernando , Grigoroiu‐Serbânescu, Maria , Hashimoto, Ryota , Heilbronner, Urs , Herms, Stefan , Hoffmann, Per , Hofmann, Andrea , Jamain, Stéphane , Jiménez, Esther , Kato, Tadafumi , König, Barbara , Kuo, Po‐Hsiu , Dalkner, Nina , Leboyer, Marion , MacQUEEN, GLENDA M. , Manchia, Mirko , Martinsson, Lina , McElroy, Susan L. , McMahon, Francis J. , Monteleone, Palmiero , Novák, Tomáš , Ozaki, Norio , Papiol, Sergi , Reich‐Erkelenz, Daniela , Reif, Andreas , Schofield, Peter R. , Seemüller, Florian , Squassina, Alessio , Stopková, Pavla , Tortorella, Alfonso , Turecki, Gustavo , Vieta, Eduard , Wright, Adam, Young, Trevor

Mayo Clinic

No container title available | October 3, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3258813/v1 | PMID 37886563 Get It

Abstract Lithium is the gold standard treatment for bipolar disorder (BD). However, its mechanism of action is incompletely understood, and prediction of treatment outcomes is limited. In our previous multi-omics study of the Pharmacogenomics of Bipolar Disorder (PGBD) sample combining transcriptomic and genomic data, we found that focal adhesion, the extracellular matrix (ECM), and PI3K-Akt signaling networks were associated with response to lithium. In this study, we replicated the results of our previous study using network propagation methods in a genome-wide association study of an independent sample of 2,039 patients from the International Consortium on Lithium Genetics (ConLiGen) study. We identified functional enrichment in focal adhesion and PI3K-Akt pathways, but we did not find an association with the ECM pathway. Our results suggest that deficits in the neuronal growth cone and PI3K-Akt signaling, but not in ECM proteins, may influence response to lithium in BD.
Abnormal Eye Movements and Hypernatremia in a 4-month-old Girl
Kruse, Sarah M., Fine, Anthony L. , Gregory, Seth W. , Fine, Anthony

Mayo Clinic

Pediatrics in Review | October 1, 2023 | Volume: 44 | Issue: S1 | Pages: S44-S47

10.1542/pir.2021-005012 | PMID 37777236 Get It

Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
Rivero, Jaydira Del , Perez, Kimberly , Kennedy, Erin B. , Mittra, Erik , Vijayvergia, Namrata , Arshad, Junaid , Basu, Sandip , Chauhan, Aman , Dasari, Arvind , Bellizzi, Andrew M. , Gangi, Alexandra , Grady, Erin , Ivanidze, Jana , Lewis, Mark A. , Mailman, Josh , Raj, Nitya , White, Sarah B. , Chan, Jennifer A. , Kunz, Pamela L. , Singh, Simron , Bergsland, Emily K. , Del Rivero, Jaydira , Dasari, Arvind N , Howe, James R , Raj, Nitya , Soares, Heloisa P , Soulen, Michael C , Kunz, Pamela L , Singh, Simron , Halfdanarson, Thorvardur R , Strosberg, Jonathan R , Bergsland, Emily K , Chauhan, Aman , Bellizzi, Andrew M , Vijayvergia, Namrata , Arshad, Junaid , Howe, James R. , Soares, Heloisa P. , Hálfdánarson, Þorvarður R. , Strosberg, Jonathan

Mayo Clinic

Journal of Clinical Oncology | September 29, 2023 | Volume: 41 | Issue: 32 | Pages: 5049-5067

10.1200/jco.23.01529 | PMID 37774329 Get It

PURPOSE To develop recommendations for systemic therapy for well-differentiated grade 1 (G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). METHODS ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS Eight randomized controlled trials met the inclusion criteria for the systematic review. RECOMMENDATIONS Somatostatin analogs (SSAs) are recommended as first-line systemic therapy for most patients with G1-grade 2 (G2) metastatic well-differentiated GI-NETs. Observation is an option for patients with low-volume or slow-growing disease without symptoms. After progression on SSAs, peptide receptor radionuclide therapy (PRRT) is recommended as systematic therapy for patients with somatostatin receptor (SSTR)–positive tumors. Everolimus is an alternative second-line therapy, particularly in nonfunctioning NETs and patients with SSTR-negative tumors. SSAs are standard first-line therapy for SSTR-positive pancreatic (pan)NETs. Rarely, observation may be appropriate for asymptomatic patients until progression. Second-line systemic options for panNETs include PRRT (for SSTR-positive tumors), cytotoxic chemotherapy, everolimus, or sunitinib. For SSTR-negative tumors, first-line therapy options are chemotherapy, everolimus, or sunitinib. There are insufficient data to recommend particular sequencing of therapies. Patients with G1-G2 high-volume disease, relatively high Ki-67 index, and/or symptoms related to tumor growth may benefit from early cytotoxic chemotherapy. For G3 GEP-NETs, systemic options for G1-G2 may be considered, although cytotoxic chemotherapy is likely the most effective option for patients with tumor-related symptoms, and SSAs are relatively ineffective. Qualifying statements are provided to assist with treatment choice. Multidisciplinary team management is recommended, along with shared decision making with patients, incorporating their values and preferences, potential benefits and harms, and other characteristics and circumstances, such as comorbidities, performance status, geographic location, and access to care. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Postvaccination Symptoms After a Fourth Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease
Lee, Yoo Jin , Li, Dalin , Debbas, Philip , Hampton, Melissa, Ebinger, Joseph E. , Chiorean, Michael , Lum, Donald , Damas, Oriana M. , Melmed, Gil , Group, CORALE-IBD Study, Banty, Andrea, Feldman, Edward J., Ha, Christina , Lee, Susie, Rabizadeh, Shervin , Stein, Theodore , Solomon, Theodore, Syal, Gaurav , Targan, Stephan R. , Vasiliauskas, Eric, Ziring, David , Bonthala, Niru, Botwin, Gregory S, Khanishian, Elizabeth, Pozdnyakova, Valeriya , Gu, Phillip , White, Shane , Zamudio, Cindy, Gonzalez, Daniel , Parry, Alyssa, Hanna, Mary , Chan, Justin, Ebinger, Joe , Wu, Min , Hoang, Amy, Wynter, Timothy , Sun, Nancy , Figueiredo, Jane C. , Merchant, Akil , Merin, Noah , Appel, Keren , Boland, Brigid S. , Charabaty, Aline , Cohen, Erica , Flynn, Ann D. , Valentine, John F. , Ehrlich, Adam C., Fudman, David , Horizon, Arash, Karayev, Dmitry, Kretzmann, Benjamin, Hou, Jason K. , Hwang, Caroline, Lazarev, Mark , Fausel, Rebecca, Reddy, Swapna , McConnell, Ryan , Mattar, Mark , Metwally, Mark, Ostrov, Arthur, Parekh, Nimisha, Raffals, Laura H., Sheibani, Sarah , Younes, Ziad , Braun, Jonathan , Melmed, Gil Y , Mujukian, Angela , Mengesha, Emebet , Cheng, Susan , McGovern, Dermot , Group, CORALE-IBD Study, Botwin, Gregory J., White, Shane, Joung, Sandy , Hoang, Amy, Reckamp, Karen L. , Kumar, Rashmi , Rubin, David T. , Siegel, Corey A , Wolf, Douglas C.

Mayo Clinic

Inflammatory Bowel Diseases | September 29, 2023 | Volume: 30 | Issue: 8 | Pages: 1430-1434

10.1093/ibd/izad198 | PMID 37773982 Get It

Imaging Characteristics of and Multidisciplinary Management Considerations for Atypical Ductal Hyperplasia and Flat Epithelial Atypia: Review of Current Literature
Harper, Laura K , Carnahan, Molly B. , Bhatt, Asha A. , Simmons, Curtis , Patel, Bhavika , Downs, Erinn , Pockaj, Barbara A. , Yancey, Kristina , Eversman, Sarah , Sharpe, Richard E. , Simmons, Curtis L , Patel, Bhavika K , Eversman, Sarah E, Harrison, Molly

Mayo Clinic

RadioGraphics | September 28, 2023 | Volume: 43 | Issue: 10 | Pages: No page available

10.1148/rg.230016 | PMID 37768862 Get It

B-122 Estimated Improvement of Sigma Error Metrics Associated with Manual Secondary Result Review, and Subsequent Artificial Intelligence Driven Quality Assurance
Rokke, Denise, Day, P., Erdahl, Sarah A , Carter, R, Jannetto, Paul J. , Bornhorst, J, Day, Patrick , Wieczorek, M

Mayo Clinic

Clinical Chemistry | September 27, 2023 | Volume: 69 | Issue: Supplement_1 | Pages: No page available

10.1093/clinchem/hvad097.456 Get It

Abstract Background Analytical and post-analytical errors are a persistent problem, which can be benchmarked using sigma metrics. Manual processes are associated with error rates of 3–4 sigma. Secondary review of manual reporting is meant to reduce/eliminate errors and is widely used, yet the true efficacy of manual secondary review is difficult to assess. Kidney stone analysis is a manually intensive process, requiring personnel to identify stone composition from spectra and to transcribe stone percent composition into an LIS system. Recently, we developed an AI program that allows for quantitative determination of kidney stone composition from spectra. This allows for a unique opportunity to estimate error rates associated with manual reporting and those following secondary review by means of subsequent AI quality assurance analysis. Methods Experienced technologists assessed stone composition and estimated the percent of each component (± 10%), based on Fourier transform infrared (FTIR) spectroscopy. These manual spectral composition assessments are secondarily reviewed by other experienced technologists for identity and percentage composition accuracy. The recently described Kidney stone AI spectral analysis (RokkStar) was implemented to assess reported stone composition identity and percent composition for agreement following secondary review in 159 334 stone reports. AI flagged discrepant reports were reviewed by personnel and reports were revised when appropriate. Secondary reviewer error detection rate was obtained by monitoring detection in a subset of 7440 kidney stones, and was that rate was extrapolated to establish secondary review error detection rate over the entire data set. The sum (total error) of estimated secondary reviewer error detection, and well as AI-mediated error detection, and all client reported errors were used to determine error rates in sigma following manual reporting, secondary review, and AI quality assurance. Results Manual entry led to an estimated 2060 errors in 159 334 stone reports, yielding an initial sigma value of 3.73. Secondary manual review resulted in an estimated 1909 (error detection rate of 92.5%) of these errors being detected over the entire report set, improving the sigma value to 4.61. Post-verification AI caught an additional 138 errors, leading to an improved post-AI sigma value of 5.27. Post-AI quality assurance, there were 13 remaining errors, 9 of which were manual reporting process deviations subsequently caught by laboratory staff, and 4 were reporting errors observed by client physicians. All 13 of these errors involved usual stone constituents or typographical errors that were not assessed by the current AI quality assurance version. Conclusion This study represents a unique large-scale estimate of efficacy of secondary result review by means of AI quality assurance review. While the presence of undetected errors cannot be completely ruled out, in this case the relative paucity of client reported errors, as well the alignment of the estimated rate of manual errors with previous reports may indicate that most errors were detected in this system. Importantly, manual secondary review improved errors rates by ∼0.9 sigma, and the use of AI further improved estimated overall sigma metric by ∼0.7, leading to a “world class” 5+ sigma level for this complex reporting process.
No Increased Mercury Release from Dental Restorations at 1.5T, 3T, or 7T MRI
Burkett, Brian J. , Rasmussen, Chad M. , Fillmore, W. Jonathan , McDonald, Robert J. , Fagan, Andrew , Erdahl, Sarah A , Eckdahl, Steven J., Welker, Kirk M. , Fagan, Andrew J , Burkett, Brian , McDonald, Jennifer S.

Mayo Clinic

Magnetic Resonance in Medicine | September 27, 2023 | Volume: 91 | Issue: 2 | Pages: 660-669

10.1002/mrm.29872 | PMID 37755142 Get It

AbstractPurposeDental amalgam contains mercury and is commonly used in dental restorations. The impact of MRI on mercury excretion from dental amalgam is not well understood across clinical field strengths, especially 7T. We investigated the effects of MRI exposure on mercury excretion using fresh, lab‐created dental amalgam restorations and in extracted teeth with old, pre‐existing restorations.MethodsDonated, unfilled human teeth (n = 120) were restored with amalgam before being stored in saline, artificial saliva, or a dry box prior to MRI scanning. The teeth were placed in individual tubes of fresh artificial saliva and scanned at 1.5T, 3T, or 7T or left unscanned as controls. Mercury concentrations were measured 24–30 h later. Donated teeth with pre‐existing restorations (n = 40) were stored in artificial saliva, scanned at 7T or left unscanned as controls, and mercury concentration tested.ResultsFor teeth extracted and restored in a laboratory, no significant difference was found (F = 2.42, P = 0.072) between mean mercury concentrations of unscanned teeth (13.72 μg/L) and teeth scanned at 1.5T (10.88 μg/L), 3T (12.65 μg/L), or 7T (8.88 μg/L). For teeth extracted with previously placed restorations, no significant difference (P = 0.288) was found between unscanned controls (4.28 μg/L) and teeth scanned at 7T (6.63 μg/L).ConclusionMRI of dental amalgam does not significantly increase mercury excretion at 1.5T, 3T, or 7T compared to unscanned teeth. This holds true for controlled laboratory restorations as well as for those placed and lived with prior to extraction and scanning, demonstrating no added risk to the clinical patient or research subject.
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
Nakamura, Yoshiaki , Mizuno, Nobumasa , Sunakawa, Yu , Canon, Jean-Luc, Galsky, Matthew D. , Hamilton, Erika , Hayashi, Hidetoshi , Jérusalem, Guy , Kim, Seung Tae , Lee, Keun‐Wook , Fonkoua, Lionel Aurelien Kankeu , Monk, Bradley J. , Oh, Do‐Youn , Pohlmann, Paula R. , Reck, Martin , Shin, Sang Joon , Takahashi, Shunji , Groisberg, Roman , Ramos, Jorge , Tan, Sherry, Stinchcombe, Thomas E. , Bekaii‐Saab, Tanios , Kankeu Fonkoua, Lionel Aurelien, Nguyen, Danny , Oh, Do-Youn , Okines, Alicia , O'Malley, David M , Reck, Martin , Sudo, Kazuki , Takahashi, Shunji , Van Marcke, Cedric , Yu, Evan Y , Groisberg, Roman , Stinchcombe, Thomas E , Bekaii-Saab, Tanios S , Hamilton, Erika P , Mizuno, Nobumasa , Pohlmann, Paula , Jerusalem, Guy , Nakamura, Yoshiaki , Canon, Jean-Luc Re , O’Malley, David M.

Mayo Clinic

Journal of Clinical Oncology | September 26, 2023 | Volume: 41 | Issue: 36 | Pages: 5569-5578

10.1200/jco.23.00606 | PMID 37751561 Get It

PURPOSE To evaluate the efficacy and safety of tucatinib and trastuzumab in patients with previously treated human epidermal growth factor receptor 2–positive (HER2+) metastatic biliary tract cancer (mBTC). METHODS SGNTUC-019 (ClinicalTrials.gov identifier: NCT04579380 ) is an open-label phase II basket study evaluating the efficacy and safety of tucatinib and trastuzumab in patients with HER2-altered solid tumors. In the biliary tract cancer cohort, patients had previously treated HER2 overexpressing or amplified (HER2+) tumors (identified with local testing) with no prior HER2-directed therapy. The primary end point was confirmed objective response rate (cORR) per investigator assessment. Patients were treated on a 21-day cycle with tucatinib (300 mg orally twice daily) and trastuzumab (8 mg/kg intravenously followed by 6 mg/kg every 3 weeks). RESULTS Thirty patients were enrolled. As of data cutoff (January 30, 2023), the median duration of follow-up was 10.8 months. The cORR was 46.7% (90% CI, 30.8 to 63.0), with a disease control rate of 76.7% (90% CI, 60.6 to 88.5). The median duration of response and progression-free survival were 6.0 months (90% CI, 5.5 to 6.9) and 5.5 months (90% CI, 3.9 to 8.1), respectively. At data cutoff, 15 patients (50.0%) had died, and the estimated 12-month overall survival rate was 53.6% (90% CI, 36.8 to 67.8). The two most common treatment-emergent adverse events (TEAEs) were pyrexia (43.3%) and diarrhea (40.0%). Grade ≥3 TEAEs were reported in 18 patients (60.0%), with the most common being cholangitis, decreased appetite, and nausea (all 10.0%), which were generally not treatment related. TEAEs led to treatment regimen discontinuation in one patient, and there were no deaths due to TEAEs. CONCLUSION Tucatinib combined with trastuzumab had clinically significant antitumor activity and was well tolerated in patients with previously treated HER2+ mBTC.